Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.31 +2.3%	$1.41	$0.65 ▼ $17.00	$13.61M	1.19	340,942 shs	196,046 shs
GELS Gelteq	$1.42	$1.80	$0.77 ▼ $5.50	$13.40M	N/A	169,476 shs	113,848 shs
LPCN Lipocine	$3.04 +0.7%	$3.18	$2.68 ▼ $6.17	$16.34M	1.24	34,481 shs	6,801 shs
THAR Tharimmune	$1.32	$1.53	$0.95 ▼ $6.39	$5.57M	1.17	119,811 shs	76,036 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	-1.54%	0.00%	-23.35%	+54.61%	-91.61%
GELS Gelteq	-7.79%	-15.71%	-19.32%	-15.48%	+141,999,900.00%
LPCN Lipocine	+1.35%	-0.33%	-5.94%	-19.30%	-20.79%
THAR Tharimmune	-5.71%	+9.09%	-21.89%	-0.38%	-54.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	2.8613 of 5 stars	3.3	4.0	0.0	0.0	2.2	0.8	1.3
GELS Gelteq	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	2.8937 of 5 stars	3.8	4.0	0.0	0.0	2.8	0.0	0.6
THAR Tharimmune	3.685 of 5 stars	3.8	5.0	0.0	0.0	3.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,945.80% Upside
GELS Gelteq	0.00	N/A	N/A	N/A
LPCN Lipocine	3.50	Strong Buy	$9.00	196.05% Upside
THAR Tharimmune	3.50	Strong Buy	$17.00	1,187.88% Upside

Current Analyst Ratings Breakdown

Latest THAR, LPCN, CTXR, and GELS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
8/11/2025	LPCN Lipocine	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$6.35 per share	N/A
GELS Gelteq	$100K	134.05	N/A	N/A	$1.30 per share	1.09
LPCN Lipocine	$4.21M	3.91	N/A	N/A	$3.16 per share	0.96
THAR Tharimmune	N/A	N/A	N/A	N/A	$0.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.05	N/A	N/A	-60.03%	-33.83%	N/A
GELS Gelteq	-$2.33M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	$10K	-$0.87	N/A	∞	N/A	N/A	-23.59%	-21.91%	N/A
THAR Tharimmune	-$12.20M	-$7.88	N/A	∞	N/A	N/A	-489.33%	-264.34%	8/15/2025 (Estimated)

Latest THAR, LPCN, CTXR, and GELS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LPCN Lipocine	-$0.41	N/A	N/A	N/A	$0.23 million	N/A
8/14/2025	Q2 2025	THAR Tharimmune	N/A	-$0.64	N/A	-$0.64	N/A	N/A
8/12/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	-$0.80	-$0.04	-$0.80	$1.92 million	$1.92 million
8/5/2025	Q2 2025	LPCN Lipocine	-$0.41	-$0.41	N/A	-$0.41	$1.00 million	$0.62 million
5/14/2025	Q2 2025	CTXR Citius Pharmaceuticals	-$1.08	-$1.27	-$0.19	-$1.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
THAR Tharimmune	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.47	0.06
GELS Gelteq	N/A	0.79	N/A
LPCN Lipocine	N/A	12.71	12.71
THAR Tharimmune	N/A	0.67	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
GELS Gelteq	N/A
LPCN Lipocine	9.11%
THAR Tharimmune	1.16%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
GELS Gelteq	N/A
LPCN Lipocine	6.35%
THAR Tharimmune	10.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
GELS Gelteq	N/A	9.44 million	N/A	N/A
LPCN Lipocine	10	5.42 million	5.08 million	No Data
THAR Tharimmune	2	4.22 million	3.80 million	Not Optionable

THAR, LPCN, CTXR, and GELS Headlines

Recent News About These Companies

Tharimmune secures key global patents for TH-104

August 13 at 11:43 PM | msn.com

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against ...

August 13 at 11:43 PM | charlotteobserver.comC

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

August 13 at 8:01 AM | accessnewswire.comA

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral ...

August 6, 2025 | freep.comF

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

August 5, 2025 | accessnewswire.comA

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

August 4, 2025 | accessnewswire.comA

Tharimmune Completes Private Placement Agreement

August 1, 2025 | msn.com

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

July 23, 2025 | accessnewswire.comA

Monday’s Insider Moves: Top Buys and Sells in US Stocks

June 24, 2025 | investing.com

Tharimmune, Inc. (NASDAQ:THAR) CEO Sireesh Appajosyula Acquires 61,496 Shares

June 24, 2025 | insidertrades.com

Tharimmune CFO Don Kim Resigns

June 17, 2025 | marketwatch.com

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

June 17, 2025 | accessnewswire.comA

Tharimmune announces executive changes and new agreements

June 13, 2025 | investing.com

Tharimmune advances opioid prophylaxis drug TH104

May 7, 2025 | investing.com

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025 | accessnewswire.comA

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025 | accessnewswire.comA

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

April 30, 2025 | accessnewswire.comA

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

April 28, 2025 | sacbee.comS

Tharimmune announces board retirements ahead of annual meeting

April 26, 2025 | investing.com

Tharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

April 15, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR, LPCN, CTXR, and GELS Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.31 +0.03 (+2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.30 -0.01 (-0.76%)

As of 07:44 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Gelteq NASDAQ:GELS

$1.42 0.00 (0.00%)

As of 04:00 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Lipocine NASDAQ:LPCN

$3.04 +0.02 (+0.66%)

Closing price 03:59 PM Eastern

Extended Trading

$3.03 -0.01 (-0.46%)

As of 07:33 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Tharimmune NASDAQ:THAR

$1.32 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$1.29 -0.03 (-2.58%)

As of 07:09 PM Eastern

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time